Advertisement

Neovasc Inc. NVCN

Set alert

Price alert · NVCN

All alert types
30.03 +30.03 —

Day range unavailable

52-week range unavailable

Open
—
Prev close
0.00
Mkt cap
83.59M
Vol
0
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
—
High
—
Forward P/E
-2.91
Beta
0.00
Short ratio
0.94
Inst. own
7.87%
Dividend
0.00
Ex-div date
Earnings
May 11, 2023
50-d avg
29.31
200-d avg
15.47
1y target
24.00

2Y chart

Chart tools
Interval

Events in this range
  • Mar 10, 2022Earnings: —; estimate -2.5; surprise —%
  • Apr 29, 2022Split: 1 for 25
  • May 12, 2022Earnings: —; estimate -1.25; surprise —%
  • Aug 11, 2022Earnings: —; estimate -1.25; surprise —%
  • Nov 10, 2022Earnings: —; estimate -2.82; surprise —%
  • Mar 31, 2023Earnings: —; estimate -1.93; surprise —%
Signals (30)
NameDateAgo
RSI: OverboughtMar 13, 20233 years ago
MACD: Sell SignalJan 31, 20233 years ago
RSI: OverboughtDec 20, 20223 years ago
RSI: OverboughtDec 12, 20223 years ago
SMA: BullishNov 25, 20223 years ago
RSI: OverboughtNov 23, 20223 years ago
SMA: BullishNov 18, 20223 years ago
MACD: Buy SignalSep 30, 20224 years ago
SMA: BearishSep 13, 20224 years ago
SMA: BullishSep 7, 20224 years ago
SMA: BearishSep 6, 20224 years ago
MACD: Sell SignalAug 16, 20224 years ago
RSI: OverboughtAug 2, 20224 years ago
RSI: OverboughtJul 28, 20224 years ago
SMA: BullishJul 6, 20224 years ago
RSI: OversoldJun 16, 20224 years ago
MACD: Buy SignalMay 18, 20224 years ago
RSI: OversoldApr 28, 20224 years ago
MACD: Sell SignalApr 6, 20224 years ago
MACD: Buy SignalMar 24, 20224 years ago
MACD: Sell SignalMar 14, 20224 years ago
SMA: BearishMar 10, 20224 years ago
SMA: BullishMar 8, 20224 years ago
SMA: BearishMar 7, 20224 years ago
SMA: BullishMar 2, 20224 years ago
MACD: Buy SignalMar 2, 20224 years ago
MACD: Sell SignalFeb 25, 20224 years ago
RSI: OversoldJan 21, 20224 years ago
MACD: Buy SignalJan 4, 20224 years ago
RSI: OversoldDec 14, 20214 years ago

Key statistics

Market cap
83.59M
Enterprise value
0
Trailing P/E
0.00
Forward P/E
-2.91
PEG ratio
0.00
Price / sales
0.00
Price / book
2.94
EPS (TTM)
-15.07
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
0
Total cash
0
Total debt
0
Return on equity
0.00%
Shares outstanding
2.76M
Short % of float
1.05%
50-day average
29.31
200-day average
15.47

Analyst view

Consensus: hold

Hold
Price target (mean) 24.00 -20.1% downside
Target (low)
20.00
Target (mean)
24.00
Target (high)
28.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy0
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

May 11, 2023

Expected May 11, 2023. Consensus EPS estimate -2.71.

Earnings history

Financials — quick view

All financials
NVCN Revenue — quarterly 1.45M
2019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 2022
NVCN Net income — quarterly -13.84M
2019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 2022
NVCN EPS — quarterly -5.04
2019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 2022

Earnings

NVCN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 11, 2023Mar 1, 20230.00———
Mar 31, 2023Dec 1, 2022-1.93———
Nov 10, 2022Sep 1, 2022-2.82———
Aug 11, 2022Jun 1, 2022-1.25———
May 12, 2022Mar 1, 2022-1.25———
Mar 10, 2022Dec 1, 2021-2.50———

Upgrades / downgrades

NVCN analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2020SVB Leerinkmain—Outperform
Nov 25, 2020H.C. Wainwrightreit—Buy
Nov 25, 2020Canaccord Genuitymain—Buy
Nov 25, 2020H.C. Wainwrightinit—Buy
Nov 25, 2020Leerink SwannmainOutperformOutperform
Nov 25, 2020Canaccord GenuitymainBuyBuy

About Neovasc Inc.

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include Tiara for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada. As of April 11, 2023, Neovasc Inc. operates as a subsidiary of Shockwave Medical, Inc.

Sector
Healthcare
Industry
Medical Devices
Country
Canada
Website
neovasc.com

News

Your note

Sign in to keep a note on NVCN — it syncs with the Stock Master app.

Insider holders

NVCN insider holders
InsiderRelationLatest transactionDateShares held
Becker (Lisa Ann McFadde)Senior Officer of IssuerExercise of rightsAug 17, 20222,451
Clark, Christopher JohnSenior Officer of IssuerExercise of rightsJun 21, 202249,095
Colen (Fredericus A)Senior Officer of IssuerExercise of rightsJun 21, 2022224,154
Gallagher (Sarah Marie Hodgson)Senior Officer of IssuerExercise of rightsAug 17, 20221,458
Geyer (Paul)10% Security Holder of IssuerAcquisition or disposition in the public marketNov 17, 202218,335
Janzen (Doug)Director of IssuerAcquisition or disposition in the public marketAug 18, 202238,779

Institution ownership

NVCN institution ownership
Holder% heldSharesValueReported
Natixis1.84%49,7781.49MDec 30, 2022
U.S. Capital Wealth Advisors, LLC0.69%18,780563.96KDec 30, 2022
Magnetar Financial LLC0.58%15,804474.59KDec 30, 2022
Choreo, LLC0.46%12,440373.57KDec 30, 2022
Morgan Stanley0.13%3,635109.16KDec 30, 2022
Bank of America Corporation0.10%2,70181.11KDec 30, 2022

Fund ownership

NVCN fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.03%85425.64KNov 29, 2022
Advertisement